By Industry | By Industry Segment | By Services and Suppliers | By Location | By Hotbed | Profile Search

Company Profile


DelMar Pharmaceuticals 

999 West Broadway
Suite 720
  British Columbia  V5Z 1K5  Canada
Phone: 1-604-629-5989 Fax:



Company News
DelMar Pharmaceuticals Presents Promising Preclinical Data On VAL-083's Potential To Treat Temozolomide-Resistant Glioblastoma Multiforme (GBM) 4/20/2015 1:07:14 PM
DelMar Pharmaceuticals Presents Updated Clinical Data On Phase I/II Study Of VAL-083 In Refractory Glioblastoma Multiforme (GBM) 4/20/2015 8:46:52 AM
DelMar Pharmaceuticals Presents Positive Preclinical Data On Val-083 For Treatment Of Non-Small Cell Lung Cancer At AACR Annual Meeting 4/20/2015 8:44:21 AM
DelMar Pharmaceuticals Adds Fourth Clinical Trial Site In Phase I/II Multicenter Study Of VAL-083 For Recurrent Malignant Glioma 4/16/2015 6:28:00 AM
DelMar Pharmaceuticals Announces Panel Participation In Cancer Advance Boston Conference On April 14, 2015 4/7/2015 9:52:45 AM
DelMar Pharmaceuticals Appoints Biopharmaceutical Industry Veteran, Erich Mohr, Ph.D., R.Psych., To The Board Of Directors 4/1/2015 11:31:50 AM
DelMar Pharmaceuticals To Present At The 27th Annual ROTH Conference On March 10, 2015 3/3/2015 10:36:30 AM
DelMar Pharmaceuticals Receives Notice Of Allowance Of Fourth U.S. Patent Covering Methods Of Use And Compositions For VAL-083 3/2/2015 9:26:07 AM
EXCLUSIVE: DelMar Pharmaceuticals CEO Outlines 2015 Plans, Looks to Clinical Cancer Trials 2/27/2015 2:42:17 PM
EXCLUSIVE: Science "Finally Catching Up" With GBM Tumors, Says DelMar Pharmaceuticals CEO 2/26/2015 12:55:08 PM